medigraphic.com
ISSN 1561-3070 (Electronic)

2014, Number 3

<< Back Next >>

Rev Cub Oftal 2014; 27 (3)

Intravitreal bevacizumab injection treatment for the macular edema secondary to the retinal vein branch occlusion

Chiang RC, Rúa MR, Llanes DS, Toledo GY, Lapido PS, Baldoquín RW

Language: Spanish
References: 49
Page: 403-415
PDF size: 192.13 Kb.


ABSTRACT

Objective: to evaluate the results of the treatment of bevacizumab in the macular edema secondary to occlusion of a branch retinal vein.
Methods: prospective, interventional, not comparative study, in 18 patients with macular edema secondary to occlusion of branch retinal vein. The treatment was of intravitreal injection of Bevacizumab (up to 3 dose) followed by grid macular if was necessary. The initial evaluation went to the 3 months of the occlusion and they were followed the patients by 12 months. It was evaluated the corrected better visual acuity, macular thickness and the occurrence of complications.
Results: the patients were 7 men (38,89%) and 11 women (61,11 %) 63,1 (44-80) years of age average. Of the treatment, 7 required 1 dose (38,89 %), 6 with 2 dose (33,33 %) and 5 with 3 dose (27,77 %) more grid macular. To the beginning the average of the best visual acuity with correction was of 0,24 (0,05-0,5) and of the macular thickness of 546,2 (283-1 020) µ. To the 12 months the best visual acuity with correction average improved at 0,65 (0,1-1,0) and the macular thickness at 181,05 (112-312) μ. there were not complications associated with proceeding.
Conclusion: the injection of bevacizumab constitutes an effective treatment in the edema secondary macular to occlusion of branch veined retiniana.


REFERENCES

  1. Scott IV. Macular Edema Associated With Retinal Vein Occlusion. Retina Today. 2010: 54-5.

  2. Rogers SL, McIntosh RL. Natural history of branch retinal vein occlusion: Evidence-based systematic review. Ophthalmology. 2010;117(6):1 094-101.

  3. Chan A, Leung LS, Blumenkranz MS. Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion. Clin Ophthalmol. 2011;5:1043-9.

  4. Shak GK. Treatment of Retinal Vein Occlusion. Individualized therapy is crucial to good patient outcomes. Retina Today. 2012:70-1.

  5. Rogers S, Mepid RL. The Prevalence of Retinal Vein Occlusion Pooled Data from Population Studies from the United States, Europe, Asia and Australia. Ophthalmology. 2010;117(2):313-9

  6. Haller JA. Evaluating and Integrating New Evidence in the Treatment of RVO. Retina Today. 2010 [citado 23 de octubre de 2012];(Supp.):[aprox 31 p.]. Disponible en: http://www.bmctoday.net/retinatoday/2010/10/ supplement/article.asp?f=evaluating-and-integrating-new-evidence-in-thetreatment- of-rvo

  7. Brown DM. New Directions in RVO Treatment. Retina Today. 2010(Supp.):3-7.

  8. Ho AC, Ip M. An Evidence-based Approach for RVO: Corticosteroids, implants and anti- VEGF therapies. Retina Today. 2011:3-6.

  9. Schutze C, Schmidt-Erfurt U. Imaging for BRVO and CRVO. Retina Today. 2011:63-8.

  10. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis and treatment modalities. Current Eye Research. 2008;33(2):111-31.

  11. Hariprasad SM. Combination Therapy for RVO. Retina Today. 2010:67-76.

  12. Boyer DS. The pathophysiology of macular edema. Retina Today. 2011 [citado: 23 de octubre de 2012];(Supp.):[aprox 8 p.]. Disponible en: http://www.bmctoday.net/retinatoday/2011/09/supplement/article.asp?f=thepatho physiology-of-macular-edema

  13. Noma H, Funatsu H, Mimura T, Tatsugawa M, Shimada K, Eguchi S. Vitreous inflammatory factors and serous macular detachment in branch retinal vein occlusion. Retina. 2012;32(1):86-91.

  14. Cousins SW, Boyer DS. New and emerging treatment paradigms for macular edema in retinal vein occlusions and diabetic retinopathy. Retina Today. 2010(Supp):1-6.

  15. Holekamp NM, Ip MS. Point/Counterpoint Early vs Late Pharmacologic Therapy for RVO. Retina Today. 2010:68-70.

  16. Herrero-Vanrell R, Cardillo JA, Kuppermann BD. Clinical applications of the sustained- release dexamethasone implant for treatment of macular edema. Clin Ophthalmol. 2011;5:139-46.

  17. Scott IV, Vanveldhuisen PC. Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: standard care versus corticosteroid for retinal vein occlusion. Study Report 10. Ophthalmology. 2011;118(2):345-52.

  18. Shahsuvaryan M. Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion. Int J ophthalmol. 2012;5(6):759-70.

  19. Haller JA, Bandello F. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema du to retinal vein occlusion. Ophthalmology. 2010;117(6):1134-46.

  20. Haller JA, Bandello F. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion, twelve- month study results. Ophthalmology. 2011;118(12):2453-60.

  21. Campochiaro PA, Heier JS. Ranibizumab for macular edema following Branch retinal vein occlusion: six month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102-12.

  22. Brown DM. Clinical implications of the Bravo and Cruise Trials. Retina Today. 2010:38-40.

  23. Kitchens J. Baseline predictors of the number of Ranibizumab retreatment injections in the Bravo study during months 6-11. Chicago: Poster presented at: American Academy of Ophthalmology Annual Meeting; October 16-19, 2010.

  24. Shapiro A, Boyer D, Nguyen QD. One year after aflibercept: where are we with therapeutic approaches for retinal vascular diseases? Retina Today. 2012:24-6.

  25. Fung A. Influence of baseline characteristics and dodsing on outcomes of antivegf therapy for retinal vein occlusions. Retina Today. 2011:58-60.

  26. Campochiaro PA. Anti-VEGF treatment for RVO: Clinical experience. Retina Today. 2011:58-60.

  27. Bandello F. Research drives treatment options for macular edema secondary to RVO. Ocular Surgery News. 2012 [citado 10 de octubre de 2012]. Disponible en: http://www.healio.com

  28. Blumenkranz M, Whitcup SM. Implant a First for ME after RVO. Benefits possible from Drug Delivery, effect on inflammation. Ophthalmology Times. 2009;34(14):50-4.

  29. Pieramaci DA review of the data regarding clinically available therapies and those on the horizon. Retina Today. 2010:1-6.

  30. Gallemare RP, Wallsh J. Management of retinal vein occlusion: what the clinical trials tell us. Retina Today. 2013:64-67.

  31. Figueroa MS, Noval S. Revisión actualizada de las terapias antiangiogénicas. Stud Ophthalmol. 2006;24(3):185-9.

  32. Figueroa MS, Contreras I. Results of Bevacizumab as the primary treatment for retinal vein occlusions. Br J Ophthalmol. 2010;94(8):1052-6.

  33. Fish GE. Intravitreous Bevacizumab in the treatment of macular edema from Branch retinal vein occlusion ad hemisphere retinal vein occlusion. Trans Am Ophthalmol Soc. 2008;106:276-300.

  34. Ogino K, Tsujikawa A, Murakami T, Muraoka Y, Kurashige Y, Yoshimura N. Grid photocoagulation combined with intravitreal bevacizumab for recurrent macular edema associated with retinal vein occlusion. Clin Ophthalmol. 2011;5:1031-6.

  35. Salinas A, Zarranz J, Caire JM, Sádaba LM, Barrio J, García A. Intravitreal Bevacizumab associated with grid laser photocoagulation in macular edema secondary to branch retinal vein occlusion. Eur J Ophthalmol. 2010;21(4):434-9.

  36. Shukla D, Behera UC, Chakraborty S, Mahalakshmi R, Prasad NM. Serous macular detachment as a predictor of resolution of macular edema with intravitreal triamcinolone injection. Ophthalmic Surg Lasers Imaging. 2009;40(2):115-9.

  37. Benson WB. A Randomized Trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion. Evidence-Based Ophthalmol. 2010;11(1):22-3.

  38. Luttrull JK. Laser for Bravo: history and current practice. Retina Today. 2011(Supp.):17-9.

  39. Kiss S. Moving beyond laser in treatment of DME, Bravo. Retina Today. 2012:48-50.

  40. Badala F. The treatment of branch retinal vein occlusion with Bevacizumab. Curr Opin Ophthalmol. 2008;19(3):234-8.

  41. Wu W, Arébalo J, Berrocal MH, Rodríguez FJ, Costa R, Cardillo J. Comparison of two doses of intravitreal Bevacizumab (avastin) for treatment of macular edema secondary to Branch Retinal Vein Occlusion: Results from the Pan-American Collaborative Retie Study Group at 6 months of follow-up. Retina. 2008;28(2):212-9.

  42. Abegg M, Tappeiner C, Barthelmes D, Wolf S, Fleischhaner J. Treatment of branch retinal vein occlusion induced macular edema with bevacizumab. BMC Ophthalmology. 2008;8:1-6.

  43. Gesine BJ, Martin L, Faik G, FockeZ, Karl UB, Szurman P. One year results after intravitreal Bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2009;247(1):27-33.

  44. Wong I, Koo S. Effect of intravitreal Bevacizumab (IVB) in treating macular edema secondary to branch retinal vein occlusion. Retina. 2010;30(4):710-1.

  45. Hu K, Horgan SE. Intravitreal Bevacizumab for macular oedema secondary to branch retinal vein occlusion: more data required. Eye. 2010;24(1):194-5.

  46. Hung KH, Lee SM. Intravitreal bevacizumab (avastin) in the treatment of macular edema associated with perfused retinal vein occlusion. J Ocul Pharmacol Ther. 2010;26(1):85-90.

  47. Chuang LH, Yeung L. Secondary ocular hypertension after intravitreal injection with 2 mg or 4 mg of triamcinolone in retinal vein occlusion. J Ocul Pharmacol Ther. 2010;26(4):325-8.

  48. Wehrli S. A lack of delayed intraocular pressure elevation in patients with intravitreal injection of bevacizumab and ranibizumab. Retina. 2012;32(7):1 295-301.

  49. Shima C. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol. 2008;86(4):372-6.




2020     |     www.medigraphic.com